Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Inside J&J's Bet to Disrupt the Da Vinci Era of Surgical Robotics

2 November 2026 · By · Wire by Fusion42

Published

2 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at mddionline.com →

◆ Verified

Fusion42 · 2 November 2026 · Fusion42 review

Johnson & Johnson received FDA De Novo authorization for its Ottava surgical robot, introducing a third competitor to Intuitive Surgical's dominant da Vinci platform in the US. Ottava aims to expand its technical capabilities, surgical indications, and geographic reach, marking a significant evolution in surgical robotics beyond current offerings.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can challenge Intuitive Surgical's dominance now that a new surgical robot with FDA clearance is entering the US market. Expand your technology and target new surgery types quickly to capture early adopters before competitors adjust.

◆ Coverage

1 source · 2 Nov 2026

◆ Related on Wire

◆ Topics

Medtechsurgical-roboticsfda-approvaljohnson-johnsonotavamedical-devices